Table 1.
Baseline demographic and clinical data of rheumatoid arthritis patients in different 12-month remission statuses
| Whole cohort (n = 273) | DAS28 remission (n = 102) | Only DAS28 remission (n = 75) | DAS28 + Boolean remission (n = 27) | Not in any remission (n = 171) | |
|---|---|---|---|---|---|
| Age (years) |
59.89 (7 to 85) |
57.12 (7 to 85) |
59.17 (26 to 85) |
51.43 (7 to 75) |
61.53 (30 to 86) |
| Disease duration (years) |
13.43 (1 to 52) |
11.1 (1 to 40) |
12,23 (1 to 40) |
7.91 (1 to 21) |
14.68 (1 to 52) |
| Female (%) |
74.7 |
68.6 |
66.7 |
74.1 |
78.4 |
| RF positivity (%) |
70.2 |
69.7 |
71.2 |
65.4 |
70.5 |
| Anti-CCP positivity (%) |
75.2 |
69.4 |
65.7 |
78.6 |
79.7 |
| DAS28(4v)-CRP |
5.33 ± 1.07 |
5.15 ± 1.1 |
5.18 ± 1.16 |
5.08 ± 0.9 |
5.44 ± 1.05 |
| TJC28 |
10.24 ± 6.86 |
8.71 ± 6.83 |
9.19 ± 7.34 |
7.37 ± 5.05 |
11.15 ± 6.73 |
| SJC28 |
9.86 ± 6.20 |
9.6 ± 6.25 |
9.73 ± 6.57 |
9.22 ± 5.36 |
10.02 ± 6.19 |
| CRP (mg/dl) |
2.76 ± 2.93 |
3.16 ± 3.14 |
3.23 ± 3.12 |
2.93 ± 3.26 |
2.53 ± 2.78 |
| PGH | 5.92 ± 2.28 | 5.6 ± 2.29 | 5.57 ± 2.33 | 5.68 ± 2.22 | 6.12 ± 2.26 |
Data presented as mean (range), mean ± standard deviation or percentage. DAS28, disease activity score based on 28-joint count; RF, rheumatoid factor; anti-CCP, anti-cyclic-citrullinated peptide antibody; DAS28(4v)-CRP, disease activity score based on 28-joint count, C-reactive protein and patient global health; TJC28, tender joint count out of 28 joints; SJC28, swollen joint count out of 28 joints; CRP, C-reactive protein; PGH, patient global health.